---
title: "Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290083508.md"
description: "Verastem (VSTM) stock rose after updated RAMP 205 trial data showed an 86% six-month survival rate and tumor shrinkage in metastatic pancreatic cancer patients. The company also initiated its TARGET-D 201 Phase 2 trial for VS-7375. Despite the positive clinical results, technical analysis indicates a bearish trend with weak momentum, though downside pressure appears to be easing."
datetime: "2026-06-17T16:45:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290083508.md)
  - [en](https://longbridge.com/en/news/290083508.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290083508.md)
---

# Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer

**Verastem, Inc.** (NASDAQ:VSTM) stock is trading higher on Wednesday as the company announced positive updated results from its RAMP 205 trial, which evaluates the efficacy of its drug combination in treating metastatic pancreatic cancer.

The trial demonstrated an 86% overall survival rate at six months, highlighting the potential impact of the treatment as it continues to mature, which may be contributing to the stock’s stability in early trading.

**Read Also: NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer**

## VSTM Stock Catalyst: RAMP 205 Pancreatic Cancer Trial Update

The RAMP 205 trial results indicate that 90% of patients presented with metastatic disease at diagnosis, and the combination therapy showed promising clinical activity, including a 68% progression-free survival rate at six months.

This news underscores the importance of Verastem’s ongoing research in addressing treatment resistance in pancreatic cancer.

At the recommended phase 2 P2D dose, the majority (83%) of patients experienced tumor shrinkage.

Nine patients remain on treatment at this dose level.

Adverse events remained generally consistent with the previously reported safety and tolerability profile, with no new safety signals observed.

On Tuesday, the oncology biopharmaceutical company dosed the first patient in the TARGET-D 201 Phase 2 trial of VS-7375, an investigational oral KRAS G12D (ON/OFF) for KRAS G12D-mutated metastatic pancreatic ductal carcinoma.

## VSTM Technical Analysis: Trend, Momentum And Key Levels

Currently, Verastem’s stock price sits at $4.01, which is about 1.1% above its 20-day simple moving average (SMA) of $4.03.

The stock remains significantly below its longer-term moving averages, trading 17.9% below the 50-day SMA of $4.96 and 25% below the 100-day SMA of $5.42, indicating a bearish trend overall.

The moving average convergence divergence (MACD) is above its signal line, suggesting that downside pressure is easing, which may indicate improving momentum compared to the previous downswing.

This positive momentum could support a potential reversal if the stock can maintain its current levels.

-   **Key Resistance**: $4.50 — a nearby level where rebounds can stall.
-   **Key Support**: $4.00 — a nearby level where buyers previously stepped in.

## How Verastem (VSTM) Ranks On Momentum And Market Signals

Below is the Benzinga Edge scorecard for Verastem, highlighting its strengths and weaknesses compared to the broader market:

-   **Momentum**: Weak (Score: 3.52) — Stock is underperforming the broader market.

**The Verdict:** Verastem’s Benzinga Edge signal reveals a weak profile, indicating challenges in gaining momentum despite recent positive news. Investors should monitor upcoming earnings and trial results closely to gauge potential shifts in market sentiment.

**VSTM Stock Price Activity:** Verastem shares were 8.48% higher at $4.345 at the time of publication on Wednesday, according to Benzinga Pro data.

_Image via Shutterstock_

**Read Also: Jim Cramer On SpaceX's Wild Rally: 'This Stock Might As Well Be Called Elon Musk'**

### Related Stocks

- [VSTM.US](https://longbridge.com/en/quote/VSTM.US.md)
- [NVCR.US](https://longbridge.com/en/quote/NVCR.US.md)

## Related News & Research

- [Verastem Advances VS-7375 Into Phase 2 Pancreatic Trial](https://longbridge.com/en/news/290061220.md)
- [VSTM: VS-7375 shows promising efficacy and safety in KRAS G12D-mutated cancers, advancing to Phase 2 trials](https://longbridge.com/en/news/290604087.md)
- [Silexion initiates Phase 2/3 SIL204 trial in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center](https://longbridge.com/en/news/294201019.md)
- [Cullinan Therapeutics (CGEM) Expected to Release Quarterly Earnings on Thursday](https://longbridge.com/en/news/294341758.md)
- [Cullinan to launch registrational Phase 2 CLN-049 trial in relapsed/refractory AML in Q3 2026](https://longbridge.com/en/news/294054305.md)